Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Euromedis Groupe SA Issues FY 2011/2012 Sales Guidance
Euromedis Groupe SA announced that it expects to report a sales growth of more than 12% in fiscal year 2011/2012, with a recovery in margins on all structures.
Latest Developments for Euromedis Groupe SA
- Euromedis Groupe SA Issues FY 2013 Revenue Guidance In Line with Analysts' Estimates; Comments on Operating Income Guidance
- Euromedis Groupe SA Confirms FY 2012/2013 Revenue Guidance
- Euromedis Groupe SA Issues FY 2012/2013 Revenue Guidance Below Analysts' Estimates
- Euromedis Groupe SA Raises FY 2011/2012 Sales Guidance
Latest Key Developments in Medical
- Biomerieux SA Receives CE Marking For VIDAS 3, The New Generation Of VIDAS
- CryoLife Inc Receives Conditional IDE Approval To Begin Clinical Trials For PerClot In The U.S.
- Essilor International SA Acquires Eight Businesses
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- Share this
- Link this
- Digg this
Follow Reuters